Crossover Randomized Comparison of Intravenous versus Intravenous/Oral Mesna in Soft Tissue Sarcoma Treated with High-Dose Ifosfamide

Clinical Cancer Research

Volumn 9, Issue 16 I, 2003, Pages 5829-5834

  Mace, Joseph R ^a   Keohan, Mary L ^b   Bernardy, Heinz ^c   Junge, Klaus ^c   Niebch, Georg ^c   Romeis, Peter ^c   Thoma, Aangelika ^c   Wagner, Thomas ^d   Mueller, Udo ^c   Demetri, George ^e   Baker, Laurence H ^a,f  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c ASTA MEDICA AG   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e HARVARD UNIVERSITY   (United States)

^f Division of Surgical Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; IFOSFAMIDE; MESNA; VINCRISTINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; FEMALE; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHLEBOTOMY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOFT TISSUE SARCOMA; URINALYSIS;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CROSS-OVER STUDIES; FEMALE; HUMANS; IFOSFAMIDE; INFUSIONS, INTRAVENOUS; MALE; MESNA; MIDDLE AGED; PROSPECTIVE STUDIES; PROTECTIVE AGENTS; SARCOMA; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME;

EID: 0347995050     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Connelly, E. F., and Budd, G. T. Ifosfamide in the treatment of soft tissue sarcoma. Semin. Oncol., 23: 16-21, 1996.
2. Brade, W., and Seeber, S. Comparative activity of ifosfamide and cyclophosphamide. Cancer Chemother. Pharmacol., 18 (Suppl. 2): S1-S9, 1986.
3. Bremner, D. N., and McCormick, J. S. Clinical trial of isophosphamide (NSC-109724)-results and side effects. Cancer Chemother. Rep., 58: 889-893, 1974.
4. Nelson, R. L., Creavan, P. J., Cohen, L. H., and Rossieck, Jr., B. E. Phase I clinical trial of a 3-day divided dose schedule of ifosfamide (NSC 109724). Eur. J. Cancer, 12: 195-198, 1976.
5. Zalupski, M., and Baker, L. H. Ifosfamide. J. Natl. Cancer Inst., 80: 556-566, 1988.
6. Cohen, M. H., Creaven, P. J., Tejada, F., Hansen, H. H., Mugia, F., Mittelman, A., and Selawry, O. S. Phase I clinical trial of isophosphamide (NSC109724). Cancer Chemother. Rep., 59: 751-755, 1975.
7. Siu, L. L. and Moore, M. J. Use of mesna to prevent ifosfamide-induced urotoxicity. Support. Care Cancer, 6: 144-154, 1998.
8. Goren, M. P. Oral administration of mesna with ifosfamide. Semin. Oncol., 23 (Suppl. 6): 91-96, 1996.
9. Schoenike, S. E., and Dana, W. J. Ifosfamide and mesna. Clin. Pharm., 9: 179-191, 1990.
10. Kerbusch, T., de Kraker, J., Keizer, H. J., van Putten, J. W., Groen, H. J., Jansen, R. L., Schellens, J. H., and Beijen, J. H. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin. Pharmacokinet., 40: 41-62, 2001.
11. Walker, D., Flinois, J. P., Monkman, J. C., Boddy, A. V., Cholerston, S., Daly, A. K., Lind, M. J., Pearsons, A. D. J., Beaunet, P. H., and Idle, J. R. Identification of the major human hepatic CYP involved in the activation and N-dechloroethylation of ifosfamide. Biochem. Pharmacol., 47: 1157-1163, 1994.
12. Chang, T. K., Weber, G. F., Crespi, C. L., and Waxman, D. J. Differential activation of cyclophosphamide and ifosfamide by cytochrome P-450 2B and 3A in human liver microsomes. Cancer Res., 53: 5629-5637, 1993.
13. Brock, N., Stekar, J., Pohl, J., Niemeyer, U., and Schefler, G. Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sulfosfamide. Arzneimittelforschung, 29:659-661, 1979.
14. Allen, L. M., and Creaven, P. J. Studies on the human pharmacokinetics of ifosfamide (NSC-109724). Cancer Treat. Rep., 60: 451-458, 1976.
15. Kovach, J. S., Schutt, A. J., Hahn, R. G., Reitmeier, R. J., and Moertel, C. G. A phase 2 study of intermittent high dose isophosphamide therapy of advanced colorectal cancer. Oncology, 29: 34-39, 1974.
16. Scheulen, M. E., Niederle, N., Bremer, K., Schütte, J., and Seeber, S. Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II study with 151 patients. Cancer Treat. Rev., 10 (Suppl. A): 93-101, 1983.
17. Araujo, C. E., and Tessler, J. Treatment of ifosfamide-induced urothelial toxicity by oral administration of mesna (sodium-2-mercaptoethane sulfonate) (Mesna) to patients with inoperable lung cancer. Eur. J. Cancer Clin. Oncol., 19: 195-201, 1983.
18. Edmonson, J. H., Buckner, J. C., Long, H. J., Loprizini, C. L., and Schaid, D. J. Phase II study of ifosfamide, etoposide, mesna in adults with advanced nonosseous sarcoma. J. Natl. Cancer Inst., 81: 863-866, 1989.
19. Goren, M. P. Oral mesna: a review. Semin Oncol, 19 (Suppl. 12): 65-71, 1992.
20. Stofer-Vogel, B., Cerny, T., Borner, M., and Lauterberg, B. H. Oral bioavailability of mesna tablets. Cancer Chemother. Pharmacol., 32: 78-81, 1993.
21. Dorr, R. T. Chemoprotectants for cancer chemotherapy. Semin. Oncol., 19 (Suppl. 2): 48-58, 1991.
22. Brock, N., and Pohl, J. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention, Comparative study on the uroprotective efficacy of thiols and other sulfur compounds. Eur. J. Cancer Clin. Oncol., 17: 1155-1163, 1981.
23. Demetri, G. D. High dose ifosfamide in the treatment of sarcomas of soft tissue and bone. Semin. Oncol., 23 (Suppl. 6): 22-26, 1996.
24. Antman, K. H., Montella, D., Rosenbaum, C., and Schwen, M. Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treat. Rep., 69: 499-504, 1985.
25. Ormstad, K., Orrineus, S., Lastbom, T., Uehara, N., Pohl, J., Stekar, and Brock, N. Pharmacokinetics and metabolism of sodium 2-mercaptoethane sulfonate in the rat. Cancer Res., 43: 333-338, 1983.
26. James, C. A., and Mant, T. G. Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. Br. J. Clin. Pharmacol., 23: 561-568, 1987.
27. Goren, M. P., Houle J-M., Bush, D. A., Li, J. T., Newman, C. E., and Brade, W. P. Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects. Clin. Cancer Res., 4: 2313-2320, 1998.
28. Goren, M. P. Combined intravenous and oral mesna in outpatients treated with ifosfamide. Cancer Chemother. Pharmacol., 40: 371-375, 1997.
29. Goren, M. P., Anthony, L. B., Jande, K. R., Johnson, D. H., Brade, W. P., Frazier, M. W., Bush, D. A., and Li, J. T. Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide. J. Clin. Oncol., 16: 616-621, 1998.